Edition:
United States

Redhill Biopharma Ltd (RDHL.TA)

RDHL.TA on Tel Aviv Stock Exchange

348.60ILa
29 May 2017
Change (% chg)

-0.40 (-0.11%)
Prev Close
349.00
Open
349.00
Day's High
349.30
Day's Low
348.00
Volume
13,638
Avg. Vol
365,914
52-wk High
610.30
52-wk Low
337.70

Latest Key Developments (Source: Significant Developments)

Redhill Biopharma reports Q1 loss per ordinary share $0.05
Wednesday, 3 May 2017 06:01am EDT 

May 3 (Reuters) - Redhill Biopharma Ltd -:Redhill Biopharma reports 2017 first quarter financial results.REDHILL BIOPHARMA ltd qtrly loss per ordinary share $0.05.  Full Article

Redhill Biopharma reports enrollment of last patient in bekinda phase II study
Monday, 24 Apr 2017 07:00am EDT 

April 24 (Reuters) - Redhill Biopharma Ltd ::Redhill Biopharma Ltd- Redhill Biopharma announces enrollment of last patient in bekinda phase II study for IBS-D.Redhill Biopharma Ltd- top-line results are expected in Q3 of 2017.Redhill Biopharma Ltd- top-line results from a phase III study with bekinda 24 mg for acute gastroenteritis and gastritis are expected in Q2 of 2017.  Full Article

Redhill Biopharma announces peer-reviewed publication of positive Yeliva® phase I study results in advanced solid tumors
Thursday, 20 Apr 2017 07:00am EDT 

April 20 (Reuters) - Redhill Biopharma Ltd :Redhill biopharma announces peer-reviewed publication of the positive yeliva® phase i study results in advanced solid tumors.Redhill biopharma ltd says phase i study with yeliva(®) in patients with advanced solid tumors successfully met its primary and secondary endpoints.Redhill biopharma ltd says results demonstrated that drug is well-tolerated and can be safely administered to cancer patients in study.Redhill biopharma ltd says is pursuing several phase i/ii clinical studies with yeliva, targeting multiple oncology and inflammatory indications.Redhill biopharma -phase ii study to evaluate efficacy of yeliva in patients with moderate to severe ulcerative colitis is to be initiated in h2 of 2017.  Full Article

Redhill Biopharma received notices of allowance from USPTO for 2 new patents covering Bekinda
Tuesday, 18 Apr 2017 08:17am EDT 

April 18 (Reuters) - Redhill Biopharma Ltd :Redhill biopharma - received notices of allowance from USPTO for 2 new patents covering Bekinda, expected to be valid until at least 2034, once granted.Redhill Biopharma Ltd - top-line results from a phase III study with Bekinda 24 mg for acute gastroenteritis and gastritis expected in Q2 2017.Redhill Biopharma - phase II study with Bekinda 12 mg for diarrhea-predominant irritable bowel syndrome is ongoing, top-line results expected in Q3 2017.  Full Article

Intelgenx and Redhill Biopharma announce marketing approval of rizaport for migraines
Thursday, 13 Apr 2017 06:00am EDT 

Intelgenx Technologies Corp - : Intelgenx and Redhill Biopharma announce marketing approval of rizaport(r) for migraines in Luxembourg . Co, Redhill expect to re-submit rizaport 505(b)(2) new drug application to FDA in q3 of 2017 .Cos are continuing discussions with additional potential commercialization partners for rizaport in U.S. , Europe, other territories.  Full Article

Redhill Biopharma- Exclusive U.S. License from Entera Health for Commercial GI Product enteragam
Wednesday, 5 Apr 2017 07:00am EDT 

Redhill Biopharma Ltd : Redhill Biopharma Ltd says exclusive U.S. License from entera health for commercial gi product enteragam .Redhill Biopharma -expects to initiate U.S. promotion of its two commercially-available gastrointestinal specialty products, donnatal and enteragam in mid-2017.  Full Article

Redhill Biopharma receives FDA orphan drug designation for cholangiocarcinoma drug
Tuesday, 4 Apr 2017 06:05am EDT 

Redhill Biopharma Ltd : Redhill Biopharma receives fda orphan drug designation for yeliva® for the treatment of cholangiocarcinoma . Redhill Biopharma Ltd says a phase i study with yeliva in patients with advanced solid tumors successfully met its primary and secondary endpoints . Redhill Biopharma -phase iia clinical study with yeliva in patients with advanced, unresectable, intrahepatic and extrahepatic cholangiocarcinoma planned in Q3 . Redhill Biopharma -to initiate phase iia clinical study with yeliva in patients with advanced,unresectable,intrahepatic,extrahepatic cholangiocarcinoma in Q3 .Redhill Biopharma -phase ii study to evaluate efficacy of yeliva in patients with moderate to severe ulcerative colitis is to be initiated in h2 of 2017.  Full Article

Redhill Biopharma says U.S. District court granted Concordia unit treble damages
Tuesday, 7 Mar 2017 08:00am EST 

Redhill Biopharma Ltd : Redhill Biopharma - U.S. District court granted Concordia unit treble damages related to false claims made by Method Pharmaceuticals, LLC, principal owner . Redhill Biopharma - Redhill expects to initiate promotion of Donnatal in Q2 of 2017 . Redhill Biopharma - court awarded Concordia treble damages of $2.2 million, an increase from original damages award of $733,000 .Redhill Biopharma - in Jan, co announced co-promotion agreement with unit of Concordia, granting co certain promotional rights in U.S. for Donnatal.  Full Article

Redhill Biopharma provides 2017 semi-annual business update
Thursday, 12 Jan 2017 06:01am EST 

Redhill Biopharma Ltd : Provides 2017 semi-annual business update . Re-submission of Rizaport NDA to FDA is expected in first half of 2017 .Top-line results are expected in mid-2017 from clinical study with Bekinda.  Full Article

Redhill Biopharma reports qtrly loss per ordinary share $0.07
Monday, 14 Nov 2016 07:10am EST 

Redhill Biopharma Ltd - : Qtrly loss per ordinary share $0.07 .Redhill biopharma reports 2016 third quarter financial results.  Full Article

More From Around the Web